- Home
- BRTX
as 11-15-2024 4:00pm EST
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MELVILLE |
| Market Cap: | 11.3M | IPO Year: | N/A |
| Target Price: | $18.00 | AVG Volume (30 days): | 34.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $3.67 | Next Earning Date: | 11-12-2024 |
| Revenue: | $377,000 | Revenue Growth: | 189.55% |
| Revenue Growth (this year): | 598.9% | Revenue Growth (next year): | 162.81% |
Stock Insider Trading Activity of BioRestorative Therapies Inc. (NV) (BRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Broadrick Dale | BRTX | 10% Owner | Oct 28 '24 | Sell | $1.58 | 1,112 | $1,756.96 | 445,933 |
Latest BioRestorative Therapies Inc. (NV) News
BRTX Breaking Stock News: Dive into BRTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
BioRestorative Therapies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
5 days ago
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
GlobeNewswire
5 days ago
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
12 days ago
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
GlobeNewswire
13 days ago
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
GlobeNewswire
18 days ago
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
GlobeNewswire
a month ago
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events
GlobeNewswire
a month ago
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Compare BRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BRTX BioRestorative Therapies Inc. (NV) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.